Author/Authors :
Park، نويسنده , , Kyung Woo and Kang، نويسنده , , Si-Hyuck and Kang، نويسنده , , Hyun-Jae and Koo، نويسنده , , Bon-Kwon and Park، نويسنده , , Byoung-Eun and Cha، نويسنده , , Kwang Soo and Rhew، نويسنده , , Jay Young and Jeon، نويسنده , , Hui-Kyoung and Shin، نويسنده , , Eun-Seok and Oh، نويسنده , , Ju Hyeon and Jeong، نويسنده , , Myung-Ho and Kim، نويسنده , , Sanghyun and Hwang، نويسنده , , Kyung-Kuk and Yoon، نويسنده , , Junghan and Lee، نويسنده , , Sung Yun and Park، نويسنده , , Tae-Ho and Moon، نويسنده , , Keon Woong and Kwon، نويسنده , , Hyuck-Moon and Hur، نويسنده , , Seung-Ho and Ryu، نويسنده , , Jae-Kean and Lee، نويسنده , , Bong-Ryul and Park، نويسنده , , Yong Whi and Chae، نويسنده , , In-Ho and Kim، نويسنده , , Hyo-Soo، نويسنده ,
Abstract :
Objectives
tudy sought to test whether the newly developed platinum chromium (PtCr)-based everolimus-eluting stent (EES) is noninferior to the cobalt chromium (CoCr)-based zotarolimus-eluting stent (ZES) in all-comers receiving percutaneous coronary intervention (PCI).
ound
rovides improved radial strength, conformability, and visibility compared with the CoCr alloy, but PtCr-based stents have not been tested in a wide range of patients receiving PCI. Also, recent case series have raised the issue of longitudinal stent deformation (LSD) with newer drug-eluting stents.
s
domly assigned 3,755 all-comers receiving PCI to PtCr-EES or CoCr-ZES. The primary outcome was target lesion failure (TLF) at 1-year post-PCI, defined as the composite of cardiac death, nonfatal target vessel–related myocardial infarction, and ischemia-driven target lesion revascularization. Post-hoc angiographic analysis was performed to qualitatively and quantitatively analyze LSD.
s
ear, TLF occurred in 2.9% and 2.9% of the population in the PtCr-EES and CoCr-ZES groups, respectively (superiority p = 0.98, noninferiority p = 0.0247). There were no significant differences in the individual components of TLF as well as the patient-oriented clinical outcome. Of 5,010 stents analyzed, LSD occurred in 0.2% and 0% in the PtCr-EES and CoCr-ZES groups, respectively (p = 0.104). There was no significant difference in post-deployment stent length ratio between the 2 stents (p = 0.352).
sions
ear, PtCr-EES was noninferior to CoCr-ZES in all-comers receiving PCI. Although LSD was observed only in PtCr-EES, both the stent length ratio and the frequency of LSD were not significantly different between the 2 stent types, and PtCr-EES was not associated with adverse clinical outcomes. (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen [HOST–ASSURE]; NCT01267734)
